## $O^2$ -(N-Hydroxy(methoxy)-2-ethanesulfonamido) Protected Diazen-1-ium-1,2-diolates: Nitric Oxide Release via a Base-induced $\beta$ -Elimination Cleavage

Zhangjian Huang and Edward E. Knaus\*,<sup>†</sup>

Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton Alberta, T6G 2N8, Canada

## **Supplementary Information**


Content:

Preparation and characterization of compounds and references	S2-S7
Proton and carbon NMR spectra for all new compounds	S8-S25

## **General Information**

Melting points were determined on a Thomas-Hoover capillary apparatus and are uncorrected. Infrared (IR) spectra were recorded as films on NaCl plates using a Nicolet 550 Series II Magna FT-IR spectrometer. <sup>1</sup>H NMR (300 MHz) and <sup>13</sup>C NMR (75 MHz) spectra were measured on a Bruker AM-300 spectrometer with TMS as the internal standard, where *J* (coupling constant) values are estimated in Hertz (Hz). Mass spectra (MS) were recorded on a Water's Micromass ZQ 4000 mass spectrometer using the ESI ionization mode. Microanalyses were performed for C, H, N by the Microanalytical Service Laboratory, Department of Chemistry, University of Alberta. Compounds 4-7, 9-17 showed a single spot on Macherey-Nagel Polygram Sil G/UV<sub>254</sub> silica gel plates (0.2 mm) using a low, medium and highly polar solvent system, and no residue remained after combustion, indicating a purity >95%. Column chromatography was performed on a Combiflash<sup>@</sup> Rf system using either a gold silica (4-7, 9-10, 12, and 15-16), or a C18 (13 and 17), column. All other reagents, purchased from the Aldrich Chemical Company (Milwaukee, WI), were used without further purification.

2-Bromoethyl thioacetate (9)



The title compound **9** was prepared using the previously reported method.<sup>1</sup> 1,2-Dibromoethane **8** (6 mL, 0.07 mol) and potassium thioacetate (4 g, 0.035 mol) were dissolved in THF (80 mL). The resulting solution was stirred at reflux for 8 h. After filtration, the filtrate was concentrated in vacuo to give a yellowish residue which was purified using ethyl acetate-hexane (1:10, v/v) as eluent to give the title compound **9** as a colorless oil (4.01 g, 63%); <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  2.36 (s, 3H, *CH*<sub>3</sub>), 3.31 (t, *J* = 4.2 Hz, 2H, BrCH<sub>2</sub>*CH*<sub>2</sub>**S**), 3.46 (t, *J* = 4.2 Hz, 2H, Br*CH*<sub>2</sub>*CH*<sub>2</sub>**S**).<sup>2</sup>

2-Iodoethyl thioacetate (10)




2-Bromoethyl thioacetate **9** (4.37 g, 24.4 mmol) was dissolved in dry acetone (50 mL) and sodium iodide (4.40 g, 29.3 mmol) was added. This mixture was allowed to stir at room temperature for 4 h during which time a precipitate (sodium bromide) formed. After filtration, the filtrate was condensed in vacuo, and then ethyl acetate (100 mL) was added. The organic solution was washed consecutively with water (80 mL), 2N sodium thiosulfate solution (80 mL), and then brine (80 mL). After the organic fraction was dried (MgSO<sub>4</sub>), the organic fraction was condensed under vacuum to give the title compound **10** as a pink oil (4.59 g, 87%) which was used without further purification; <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  2.35 (s, 3H, *CH*<sub>3</sub>), 3.22-3.28 (m, 2H, ICH<sub>2</sub>*CH*<sub>2</sub>S), 3.31-3.37 (m, 2H, I*CH*<sub>2</sub>*CH*<sub>2</sub>S). <sup>3</sup>

Sodium 1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (11)


A solution of pyrrolidine (32.8 mL, 0.397 mol) in acetonitrile (100 mL) and ether (100 mL) was mixed with 25% sodium methoxide in methanol (94 mL, 0.4 mol). The resulting solution was flushed with nitrogen, charged with 40-50 psi of NO, and stirred at room temperature. Two days later, the pressure was released and the product was collected by filtration, washed with ether, and dried under vacuum to give **11** (30.3 g, 51%) as a white powder; <sup>1</sup>H NMR (D<sub>2</sub>O):  $\delta$  1.89 (m, 4H), 3.15 (m, 4H).<sup>4</sup>

 $O^2$ -(2-Acetthioethyl) 1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (12)



The PYRRO/NO **11** (3.33 g, 21.8 mmol) was added to a mixture of sodium bicarbonate (500 mg, 6.0 mmol) and 15-crown-5 (5 drops) in dry DMF (20 mL) and dry THF (20 mL) at room temperature with stirring during 5 min. 2-Iodoethyl thioacetate **10** (4.55 g, 20.0 mmol) was added drop wise, and the reaction was allowed to proceed at room temperature for 15 h with stirring under argon. Ethyl acetate (200 mL) was added to dilute the reaction, the solids were filtered off, and the organic phase was washed with water (5 × 80 mL) and the organic fraction was dried (MgSO<sub>4</sub>). The solvent was removed in vacuo to give a liquid residue which was purified by flash column chromatography using EtOAc-hexane (1:2, v/v) as eluent to furnish the title compound **12** (1.01 g, 20%) as a brown oil; IR (film): 2985, 2935, 2879, 1698, 1486 cm<sup>-1</sup>; ESI-MS: 256 [M+Na]<sup>+</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  1.92-1.97 (m, 4H, pyrrolidin-1-yl H-3 and H-4), 2.35 (s, 3H, *CH*<sub>3</sub>), 3.22 (t, *J* = 6.8 Hz, 2H, OCH<sub>2</sub>CH<sub>2</sub>S), 3.53-3.57 (m, 4H, pyrrolidin-1-yl H-2 and H-5), 4.26 (t, *J* = 6.8 Hz, 2H, OCH<sub>2</sub>CH<sub>2</sub>S); <sup>13</sup>C NMR (CDCl<sub>3</sub>):  $\delta$  22.8, 30.5, 50.9, 61.7, 71.3, 194.8.

 $O^2$ -(2-Oxysulfonylethyl sodium salt) 1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (13)




The thioacetate **12** (330 mg, 1.42 mmol) was dissolved in  $H_2O_2$  (30% w/v, 0.72 mL) and AcOH (2.2 mL). Sodium acetate (140 mg, 1.70 mmol) was added, the reaction was allowed to proceed with stirring for 10 h at 55 °C, and then 10% Pd/C (about 1 g) was added to destroy the excess peroxide. After filtration,  $H_2O$  (5 mL) was added to the filtrate, and this aqueous solution was washed with ethyl acetate (2 × 5 mL). The aqueous solution was coevaporated with ethanol (2 × 5 mL) under reduced pressure to afford the crude sulfonate sodium salt **13** (244 mg, 66 %). Purification was performed on a C18 column (diameter 2 cm × length 7 cm) using  $H_2O$ -acetonitrile (95:5, v/v) as eluent to furnish the **13** as a colorless syrup; IR (film): 2960, 2879, 1658, 1201 cm<sup>-1</sup>; ESI-MS: 238 [M-Na]<sup>-</sup>;

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>):  $\delta$  1.80-1.89 (m, 4H, pyrrolidin-1-yl H-3 and H-4), 2.83 (t, *J* = 7.9 Hz, 2H, OCH<sub>2</sub>*CH*<sub>2</sub>S), 3.48-3.65 (m, 4H, pyrrolidin-1-yl H-2 and H-5), 4.25 (t, *J* = 7.9 Hz, 2H, OCH<sub>2</sub>CH<sub>2</sub>S); <sup>13</sup>C NMR (DMSO-d<sub>6</sub>):  $\delta$  22.2, 50.2, 50.5, 69.4.

 $O^2$ -(2-Hydroxyaminosulfonylethyl) 1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (4)

The sulfonic acid sodium salt **13** (250 mg, 0.96 mmol) was dissolved in DMF (3 mL) and SOCl<sub>2</sub> (0.35 mL) was added drop wise. The reaction mixture was stirred at 25 °C for 1.5 h, poured into cold water (30 mL), and extracted with diethyl ether (3 x 30 mL). The combined organic fractions were washed with 2N HCl and brine, and the organic fraction was dried (MgSO<sub>4</sub>). After concentration in vacuo at room temperature, the resulting brown syrup of the sulfonyl chloride product was used immediately for the next reaction without further purification. This ethanesulfonyl chloride residue was dissolved in dry THF (5 mL) and then hydroxylamine hydrochloric (200 mg, 2.88 mmol) and potassium carbonate (793 mg, 5.75 mmol) were added. The reaction mixture was vigorously stirred at room temperature until the sulfonyl chloride had completely disappeared (TLC; EtOAc-hexane, 1:2, v/v) in about 2 hours. The reaction mixture was filtered through a pad of Celite that provided a clear filtrate which was added to ethyl acetate (20 mL), this mixture was washed with water (20 mL) and brine (20 mL), and the organic fraction was dried (MgSO<sub>4</sub>). Removal of the solvent from the organic fraction in vacuo gave a residue that was purified by flash silica gel column chromatography using n-hexane-EtOAc (2:1, v/v) as eluent to afford the title compound **4** (61 mg, 20%, two steps) as a white solid; mp 111-113 °C; IR (film): 3368, 3220, 2967, 2923, 1743, 1261 cm<sup>-1</sup>; ESI-MS: 255 [M+H]<sup>+</sup>, 253 [M-H]<sup>-</sup>; <sup>1</sup>H NMR (DMSO-d<sub>6</sub>):  $\delta$  1.85-1.89 (m, 4H, pyrrolidin-1-yl H-3 and H-4), 3.44-3.48 (m, 4H, pyrrolidin-1-yl H-2 and H-5), 3.56 (t, *J* = 6.1 Hz, 2H, OCH<sub>2</sub>CH<sub>2</sub>S), 4.43 (t, *J* = 6.1 Hz, 2H, OCH<sub>2</sub>CH<sub>2</sub>S), 9.19 and 9.71 (two d, *J* = 3.7 Hz, 1H each, *HO*-NH); <sup>13</sup>C NMR (DMSO-d<sub>6</sub>):  $\delta$  22.3, 46.1, 50.5, 65.9. Anal. Calcd for C<sub>6</sub>H<sub>14</sub>N<sub>4</sub>O<sub>5</sub>S: C, 28.34; H, 5.55. Found: C, 28.10; H, 5.55.

 $O^{2}$ -(2-Methoxyaminosulfonylethyl) 1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (5)




The sulfonic acid sodium salt **13** (250 mg, 0.96 mmol) was dissolved in DMF (3 mL) and SOCl<sub>2</sub> (0.35 mL) was added drop wise. The reaction mixture was allowed to stir at 25 °C for 1.5 h, poured into cold water (30 mL), and extracted with ethyl ether (3 x 30 mL). The combined organic fractions were washed with 2N HCl solution and brine, and the organic fraction was dried (MgSO<sub>4</sub>). After concentration in vacuo at room temperature, the resulting brown syrup of the sulfonyl chloride product was dissolved in dry THF (5 mL), and then methoxylamine hydrochloride (160 mg, 1.92 mmol) and NaHCO<sub>3</sub> (320 mg, 3.84 mmol) were added. The reaction mixture was vigorously stirred at 25 °C until the sulfonyl chloride had completely disappeared (TLC; EtOAc-hexane, 1:2, v/v) in about 3 hours. The reaction mixture was filtered through a pad of Celite that provided a clear filtrate which was added to ethyl acetate (20 mL), this mixture was washed with water (20 mL) and brine (20 mL), and the organic fraction was dried (MgSO<sub>4</sub>). Removal of the solvent from the organic fraction in vacuo

gave a residue that was purified by flash silica gel column chromatography using n-hexane-EtOAc (2:1, v/v) as eluent to afford the title compound **5** (72 mg, 28%, two steps) as a white solid; mp 85-86 °C; IR (film): 3228, 3220, 2968, 2941, 1742, 1338, 1172 cm<sup>-1</sup>; ESI-MS: 269 [M+H]<sup>+</sup>, 267 [M-H]<sup>-</sup>; <sup>1</sup>H NMR (DMSO-d<sub>6</sub>):  $\delta$  1.84-1.89 (m, 4H, pyrrolidin-1-yl H-3 and H-4), 3.43-3.47 (m, 4H, pyrrolidin-1-yl H-2 and H-5), 3.58 (t, *J* = 6.1 Hz, 2H, OCH<sub>2</sub>CH<sub>2</sub>S), 3.67 (s, 3H, OCH<sub>3</sub>), 4.42 (t, *J* = 6.1 Hz, 2H, OCH<sub>2</sub>CH<sub>2</sub>S), 10.1 (s, 1H, NH); <sup>13</sup>C NMR (DMSO-d<sub>6</sub>):  $\delta$  22.2, 47.3, 50.4, 64.4, 65.7. Anal. Calcd for C<sub>7</sub>H<sub>16</sub>N<sub>4</sub>O<sub>5</sub>S: C, 31.34; H, 6.01. Found: C, 31.68; H, 6.29.

(S)-1-[2-(Hydroxymethyl)pyrrolidin-1-yl]diazen-1-ium-1,2-diolate sodium salt (14)


(*S*)-2-(Hydroxymethyl)pyrrolidine (5.0 g, 49 mmol) was dissolved in a 1:1 mixture of THF-diethyl ether (100 mL) and sodium methoxide (56 mmol, 11 mL of a 30% w/v solution in methanol) was added with stirring at room temperature during 5 min. This mixture was flushed with dry argon for 5 min, and the reaction was allowed to proceed under an atmosphere of nitric oxide (40-50 psi internal pressure) with stirring at room temperature for 24 h. The product, which precipitated as a fine white powder, was isolated by filtration and then washing with dry diethyl ether to give the title compound **14** (7.7 g, 85.0%); mp 123-127 °C;<sup>5 1</sup>H NMR (D<sub>2</sub>O):  $\delta$  1.64-2.09 (m, 4H, pyrrolidin-1-yl H-3 and H-4), 3.10-3.57 (m, 5H, pyrrolidin-1-yl H-2, H-5 and *CH*<sub>2</sub>OH).<sup>5</sup>

 $(S)-O^2-(2-Acetthioethyl)$  1-[2-(hydroxymethyl)pyrrolidin-1-yl]diazen-1-ium-1,2-iolate (15)




The title compound **15** was synthesized, using a method similar to that used to prepare **12** starting from 2-iodoethyl thioacetate **10** and **14**, in 24% yield as a brownish oil; IR (film): 3431, 2953, 2874, 1710, 1452; ESI-MS: 286 [M+Na]<sup>+</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  1.76-1.84 (m, 1H, pyrrolidin-1-yl H-3), 1.90-2.09 (m, 3H, pyrrolidin-1-yl H'-3, H-4 and H'-4), 2.35 (s, 3H, *CH*<sub>3</sub>), 2.77 (brs, 1H, CH<sub>2</sub>O*H*), 3.21 (t, *J* = 6.1 Hz, 2H, OCH<sub>2</sub>*CH*<sub>2</sub>S), 3.53-3.66 (m, 3H, pyrrolidin-1-yl H'-5, H-5 and CH*H*'OH), 3.76 (dd, *J* = 11.6, 3.6 Hz, 1H, *CH*H'OH), 4.03-4.10 (m, 1H, pyrrolidin-1-yl H-2), 4.28 (t, *J* = 6.1 Hz, 2H, O*CH*<sub>2</sub>CH<sub>2</sub>S); <sup>13</sup>C NMR (CDCl<sub>3</sub>):  $\delta$  23.0, 26.8, 27.9, 30.5, 52.8, 64.1, 65.2, 17.6, 194.9.

(S)-O<sup>2</sup>-(2-Acetthioethyl) 1-[2-(acetoxymethyl)pyrrolidin-1-yl]diazen-1-ium-1,2-diolate (16)




Compound **15** (160 mg, 0.61 mmol) and 4-dimethylaminopyridine (DMAP) (148 mg, 1.21 mmol) were dissolved in dry CH<sub>2</sub>Cl<sub>2</sub> (8 mL), acetyl bromide (150 mg, 1.22 mmol) was added with stirring at ice-water bath temperature, and the reaction was allowed to proceed at room temperature for 1 h. Additional CH<sub>2</sub>Cl<sub>2</sub> (20 mL) was added to the reaction mixture, the combined organic phase was washed with 1N HCl solution (2 × 10 mL), brine (10 mL), and the organic fraction was dried (Mg<sub>2</sub>SO<sub>4</sub>). After filtration and removal of the solvent, the title compound **16** was obtained as a brownish oil (160 mg, 86%); IR (film): 2957, 2877, 1750, 1704, 1247; ESI-MS: 328 [M+Na]<sup>+</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  1.74-1.82 (m, 1H, pyrrolidin-1-yl H-3), 1.92-1.99 (m, 3H, pyrrolidin-1-yl H'-3, H-4 and H'-4), 2.05 (s, 3H, OCO*CH*<sub>3</sub>), 2.33 (s, 3H, SCO*CH*<sub>3</sub>), 3.21 (t, *J* = 6.1 Hz, 2H, OCH<sub>2</sub>CH<sub>2</sub>S), 3.50-3.64 (m, 2H, pyrrolidin-1-yl H-5' and H-5), 4.18-4.56 (m, 3H, pyrrolidin-1-yl H-2 and *CH*<sub>2</sub>OAc), 4.26 (t, *J* = 6.1 Hz, 2H, OCH<sub>2</sub>CH<sub>2</sub>S); <sup>13</sup>C NMR (CDCl<sub>3</sub>):  $\delta$  20.9, 22.7, 26.8, 27.1, 30.5, 52.7, 61.0, 65.4, 71.5, 170.6, 194.8.

 $O^2$ -(2-Oxysulfonylethyl sodium salt) 1-[2-(acetoxymethyl)pyrrolidin-1-yl]diazen-1-ium-1,2-diolate (17)



The title compound **17** was synthesized, using a method similar to that used to prepare **13** starting from **16**, in 75% yield, as a brownish syrup; IR (film): 2960, 2874, 1755, 1697, 1200 cm<sup>-1</sup>; ESI-MS: 310 [M-Na]<sup>-</sup>; <sup>1</sup>H NMR (DMSO-d<sub>6</sub>):  $\delta$  1.67-1.71 (m, 1H, pyrrolidin-1-yl H-3), 1.82-2.07 (m, 3H, pyrrolidin-1-yl H'-3, H-4 and H'-4), 2.00 (s, 3H, OCO*CH*<sub>3</sub>), 2.83 (t, *J* = 7.9 Hz, 2H, OCH<sub>2</sub>*CH*<sub>2</sub>S), 3.36-3.51 (m, 2H, pyrrolidin-1-yl H'-5 and H-5), 4.08-4.12 (m, 3H, pyrrolidin-1-yl H-2 and *CH*<sub>2</sub>OAc), 4.27 (t, *J* = 7.9 Hz, 2H, OCH<sub>2</sub>CH<sub>2</sub>S); <sup>13</sup>C NMR (DMSO-d<sub>6</sub>):  $\delta$  20.5, 22.1, 26.2, 50.2, 52.2, 59.5, 64.9, 69.6, 170.0.

 $(S)-O^2-(2-Hydroxyaminosulfonylethyl)$  1-[2-(acetoxymethyl)pyrrolidin-1-yl]diazen-1-ium-1,2-diolate (6)



The title compound **6** was synthesized, using a method similar to that used to prepare **4** starting from **17**, in 23% yield (two steps), as a brownish oil; IR (film): 3371, 3225, 2969, 2929, 1748, 1261 cm<sup>-1</sup>;  $[\alpha]^{21.0}_{D} = -66.10$  (c 0.1800; EtOAc); ESI-MS: 349 [M+Na]<sup>+</sup>, 325 [M-H]<sup>-</sup>; <sup>1</sup>H NMR (DMSO-d<sub>6</sub>):  $\delta$  1.55-1.58 (m, 1H, pyrrolidin-1-yl H-3), 1.84-2.03 (m, 3H, pyrrolidin-1-yl H'-3, H-4 and H'-4), 2.00 (s, 3H, OCO*CH*<sub>3</sub>), 3.41-3.51 (m, 2H, pyrrolidin-1-yl H'-5 and H-5), 3.55 (t, *J* = 6.1 Hz, 2H, OCH<sub>2</sub>*CH*<sub>2</sub>S), 4.07-4.11 (m, 2H, *CH*<sub>2</sub>OAc), 4.14-4.17 (m, 1H, pyrrolidin-1-yl H-2), 4.44 (t, *J* = 6.1 Hz, 2H, O*CH*<sub>2</sub>CH<sub>2</sub>S), 9.19 and 9.69 (two d, *J* = 3.1 Hz, 1H each, N*H*-O*H*); <sup>13</sup>C NMR (DMSO-d<sub>6</sub>):  $\delta$  20.5, 22.2, 26.2, 46.2, 52.1, 59.6, 64.8, 66.1, 170.1. Anal. Calcd for C<sub>9</sub>H<sub>18</sub>N<sub>4</sub>O<sub>7</sub>S: C, 33.13; H, 5.56; N,

17.17. Found: C, 35.23; H, 5.95; N, 15.67 (Diazen-1-ium-1,2-diolates such as **6** often do not give microanalytical data within  $\pm$  0.4% of theoretical values even when the compound is pure).

 $(S)-O^2-(2-Methoxyaminosulfonylethyl)$  1-[2-(acetoxymethyl)pyrrolidin-1-yl]diazen-1-ium-1,2-diolate (7)

The title compound 7 was synthesized, using a method similar to that used to prepare **5** starting from **17**, in 21% yield (two steps), as a brownish oil; IR (film): 3204, 2961, 2921, 2865, 1742, 1266, 1028 cm<sup>-1</sup>;  $[\alpha]^{21.0}_{D} = -35.69$  (c 0.1300; EtOAc); ESI-MS: 363 [M+Na]<sup>+</sup>, 339 [M-H]<sup>-</sup>; <sup>1</sup>H NMR (DMSO-d<sub>6</sub>):  $\delta$  1.68-1.73 (m, 1H, pyrrolidin-1-yl H-3), 1.84-2.06 (m, 3H, pyrrolidin-1-yl H'-3, H-4 and H'-4), 2.01 (s, 3H, OCO*CH*<sub>3</sub>), 3.41-3.54 (m, 2H, pyrrolidin-1-yl H'-5 and H-5), 3.58 (t, *J* = 6.1 Hz, 2H, OCH<sub>2</sub>*CH*<sub>2</sub>S), 3.66 (s, 3H, O*CH*<sub>3</sub>), 4.08-4.11 (m, 2H, *CH*<sub>2</sub>OAc), 4.13-4.19 (m, 1H, pyrrolidin-1-yl H-2), 4.43 (t, *J* = 6.1 Hz, 2H, O*CH*<sub>2</sub>*CH*<sub>2</sub>S), 10.2 (s, 1H, N*H*); <sup>13</sup>C NMR (DMSO-d<sub>6</sub>):  $\delta$  20.5, 22.2, 26.2, 47.3, 52.1, 59.6, 64.4, 64.8, 65.8, 170.1. Anal. Calcd for C<sub>10</sub>H<sub>20</sub>N<sub>4</sub>O<sub>7</sub>S: C, 35.29; H, 5.92; N, 16.46. Found: C, 36.83; H, 6.08; N, 15.25 (Diazen-1-ium-1,2-diolates such as **7** often do not give microanalytical data within ± 0.4% of theoretical values even when the compound is pure).

The recovery of ibuprofen from *N*-methoxyethanesulfonylamide ester of ibuprofen **3** 

*N*-methoxyethanesulfonylamide ester of ibuprofen **3** (30 mg, 0.087 mmol) <sup>6</sup> was dissolved in dry THF (2 mL), and then 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (60 mg, 0.39 mmol) was added. The reaction was proceeded at room temperature for 16 h during which time a white precipitate formed. The reaction mixture was acidified to pH 3-4 using 1N HCl solution, and then was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 5 mL). The combined organic fractions were collected and washed with brine (8 mL), dried (Mg<sub>2</sub>SO<sub>4</sub>). Removal of the solvent from the organic fraction in vacuo gave a residue that was purified by flash silica gel column chromatography using n-hexane-EtOAc (3:1, v/v) as eluent to afford ibuprofen (13 mg, 72%) as a white solid; <sup>1</sup>H NMR (CDCl<sub>3</sub>): <sup>1</sup>H NMR (DMSO-d<sub>6</sub>):  $\delta$  0.90 (d, *J* = 6.7 Hz, 6H, (*CH*<sub>3</sub>)<sub>2</sub>CHCH<sub>2</sub>), 1.50 (d, *J* = 7.4 Hz, 3H, CH*CH*<sub>3</sub>), 1.85 (heptet, *J* = 6.7 Hz, 1H, (CH<sub>3</sub>)<sub>2</sub>CHCH<sub>2</sub>), 2.45 (d, *J* = 6.7 Hz, 2H, (CH<sub>3</sub>)<sub>2</sub>CHCH<sub>2</sub>), 3.73 (q, *J* = 7.4 Hz, 1H, Ar*CH*), 7.10 (d, *J* = 8.0 Hz, 2H, phenyl H-3 and H-5), 7.19 (d, *J* = 8.0 Hz, phenyl H-2 and H-6).

- 1. Tang, J.; Zhang, X.; Zhu, H.; Luo, S. Journal of Guizhou Normal University (Nature Sciences) 2006, 24, 98-102.
- 2. Bauer, L.; Suresh, K. S.; Ghosh, B. K. J. Org. Chem. 1965, 30, 949-951.
- 3. Iwin. Zhurnal Obshchei Khimii 1952, 22, 267-271.
- 4. Saavedra, J. E.; Billiar, T. R.; Williams, D. L.; Kim, Y.; Watkins, S. C.; Keefer, L. K. J. Med. Chem. 1997, 40, 1947-1954.
- 5. Velázquez, C. A.; Chen, Q. H.; Citro, M. L. Keefer, L. K.; Knaus, E. E. J. Med. Chem. 2008, 51, 1954–1961.
- 6. Huang, Z.; Velázquez, C. A.; Abdellatif, K. A.; Chowdhury, M. A.; Reisz, J. A.; DuMond, J. F.; King, S. B.; Knaus, E. E. J. Med. Chem. 2010, In Press.

